Miscellaneous

In this section abstracts of Nanobiotix can be found which do not related to NBTXR3.

2018 – ASTRO – NBTXR3 Anti-Tumor Immune Response

Soft tissue sarcoma (STS) is a rare type of cancer, which occurs in tissues connecting, supporting and/or surrounding other structures of the body, like muscle, fat, etc. More than 50 subtypes of STS exist, characterized by a strong propensity to local recurrence and metastatic spreading. Consistently, the immune microenvironment in sarcomas is highly variable. A new class of high electron density material, hafnium oxide, was designed at the nanoscale to efficiently absorb ionizing radiation from within the tumor cells and increase the dose deposition into the tumor. […]

Continue Reading...

2018 – OncoRad – NBXTR3 in HNSCC and NSCLC with anti-PD1

Recent clinical studies have demonstrated the efficacy of anti-PD-1 in recurrent/metastatic HNSCC and upfront metastatic NSCLC patients. However, most patients with recurrent/metastatic HNSCC demon-strate innate (primary) resistance to checkpoint inhibition and do not respond to initial therapy and only a subset of metastatic HNSCC/NSCLC patients benefits from this treatment. […]

Continue Reading...

2018 – ASCO – NBTXR3 generates an anti-tumor immune response

The enclosed abstract was presented at the 13th Journées cancéropole Grand Sud-Ouest at Poitiers. The abstract Hafnium oxide nanoparticles as an emergent promising treatment for solid tumors describes how hafnium oxide nanoparticles were designed at the nanoscale in the form of crystalline 50nm-particles to efficiently absorb ionizing radiation and increase the radiation dose deposited – “hot spots” of energy deposit – from within the tumor cells for efficient cell killing. […]

Continue Reading...

2017 – Abstract – 13th Journées cancéropole GSO – HfO2 nanoparticles in solid tumors

The enclosed abstract was presented at the 13th Journées cancéropole Grand Sud-Ouest at Poitiers. The abstract Hafnium oxide nanoparticles as an emergent promising treatment for solid tumors describes how hafnium oxide nanoparticles were designed at the nanoscale in the form of crystalline 50nm-particles to efficiently absorb ionizing radiation and increase the radiation dose deposited – “hot spots” of energy deposit – from within the tumor cells for efficient cell killing. […]

Continue Reading...

2017 – Abstract – 35th CFS – Hafnium Oxide Nanoparticles: An Emergent Promising Treatment for Solid Tumors

Hafnium oxide nanoparticles: an emergent promising treatment for solid tumors To improve tumor response, radiotherapy (RT) has been combined with chemical agents, radiosensitizers and monoclonal antibodies. However, the complexity of these associations in terms of pharmacology, local control, clinical outcome benefits or patient quality of life underlines the need for the development of new therapeutic approaches. […]

Continue Reading...

2017 – Abstract Conference Immunotherapy Radiotherapy Combinations NYC

Hafnium oxide, an electron-dense material, was designed at the nanoscale to increase the radiation dose deposited from within the cancer cells: “Hot spot” of energy deposit where the nanoparticles are when exposed to radiation therapy (RT). Preclinical studies have demonstrated increase of cancer cells killing in vitro and marked antitumor efficacy in vivo with presence of these nanoparticles […]

Continue Reading...

2015 – Clinical Sciences and Drug Discovery Abstract – Use of metals as nano-sized radiation enhancers – Pottier et al.

Since the discovery of cisplatin about 40 years ago, the design of innovative metal-based anticancer drugs is a growing area of research. Metal elements offer specific characteristics due to their intrinsic properties and could be used in relation to their final state: a metal complex, a radionuclide, a metal-based nanoparticle product. Transition metal coordination complexes interact with cell molecular targets, affecting biochemical functions resulting in cancer cell destruction. Radionuclides are another way to use metals as anticancer therapy. The metal nucleus of the unstable radionuclide becomes stable by emitting energy. The biological effect in different tissues is obtained by the absorption of this energy from the radiation emitted by the radionuclide, the principal target generally agreed for ionizing radiations being DNA. A new area of clinical research is now emerging using the same experimental metal elements, but in a radically different manner: metals and metal oxides used as crystalline nanosized radiation enhancers particles. The use of metals as a high electron density material tailored at the nanoscale when exposed to radiotherapy is a unique approach that can allow entry to the cell and make feasible the absorption/deposition of a high-energy dose within the tumor cell (on/off activity). Therefore, high electron density metal or metal oxide nanoparticles may bring well known physical mode of action, that of radiotherapy, within malignant cells and achieve the paradigm of local cancer treatment.

Continue Reading...

2011 – CLINAM Abstract – Thermosensitive Magnetoliposomes for MRI-Guided Drug Delivery – Meyr et al.

Congress: CLINAM, 23rd May 2011 – The development of new activatable drug nanocarriers, with multiple functionalities, presents a promising approach for cancer treatment. Improved drug delivery and controlled drug release at the tumor site may have considerable benefit by increasing treatment efficacy while reducing side effects and toxicity. Further, the possibility to monitor both nanocarrier accumulation and drug release via current clinical imaging techniques may be particularly relevant for an optimal treatment.

Continue Reading...

2010 – GDR Photomed Abstract – Silica Nanoparticles for Photodynamic Therapy – Thienot et al.

Photodynamic therapy in the elderly and heavily pretreated cancer patient populations may represent a promising therapeutical option in the management of malignant diseases provided that different approaches bring real improvement for its clinical application. Silica-based nanocarrier encapsulating photosensitizers, the protoporphyrin IX (Pp IX), have been designed to improve the tumor bioavailability, to reduce photosensitizer accumulation in the skin and to differentially deliver the nanocarriers to cell organelles.

Continue Reading...

By continuing to use the site, you agree to the use of cookies.En poursuivant votre navigation sur ce site, vous acceptez l’utilisation de cookies. More information.En savoir plus.

The cookie settings on this website are set to “allow cookies” to give you the possibility to switch between languages in a way that this will not interfere with page navigation. If you continue to use this website without changing your cookie settings or you click “Accept” below then you are consenting to this.Par défaut, les paramètres de ce site autorisent les cookies pour vous permettre notamment de naviguer entre les différentes langues disponibles. Nous utilisons des cookies pour vous proposer un site internet facile d'utilisation, sécurisé et fonctionnel. Si vous les autorisez également, cliquez sur « Accepter » ou poursuivez simplement votre navigation.

CloseFermer